Gland Pharma Limited — Board Meeting, 15-05-2026: Outcome of Board Meeting

Gland Pharma's Board approved Q4 FY26 consolidated results: Revenue rose 22% YoY to ₹1,742.8 Cr, PAT soared 97% to ₹366.7 Cr. For FY26, revenue increased 14% to ₹6,430.7 Cr, with PAT up 50% to ₹1,045.5 Cr. A ₹20/share final dividend was also approved.